HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dexmedetomidine versus remifentanil for sedation under monitored anesthetic care in complex endovascular aortic aneurysm repair: a single center experience with mid-term follow-up.

AbstractBACKGROUND:
Sedation protocols in patients undergoing complex endovascular aortic aneurysm repair are not fully investigated. The aim of this study was to compare a dexmedetomidine (DEX) based sedation protocol with a remifentanil-based sedation protocol.
METHODS:
Seventy-nine consecutive patients undergoing complex endovascular aortic repair were enrolled and retrospectively analyzed. Forty-two received 0.03 mg/kg midazolam intravenous bolus with remifentanil (0.075-0.1 μg/kg/min for 10 minutes followed by continuous infusion 0.050-0.25 μg/kg/min) and 37 DEX (1 μg/kg over 10 minutes and continuous infusion 0.50-0.75 μg/kg/hour) to achieve an Observer Assessment of Alertness/Sedation Scale (OAAS) ≤4, a Richmond Agitation/Sedation Scale (RASS) ≤-2 and a Visual Analogic Scale (VAS) <4. The primary endpoint was patients' satisfaction. Secondary endpoints included assessment of sedation and pain, the incidence of perioperative hemodynamic or gas exchange imbalance, and 36 month-mortality.
RESULTS:
Remifentanil group showed a higher satisfaction rate than DEX (P<0.001). Patients on DEX were more sedated than remifentanil according to OAAS (3 [2-3] vs. 4 [3-4]; P=0.001) and RASS (-2[-3/-2] vs. -2[-2/-2]; P=0.001) with no difference in VAS (2 [1-3] vs. 2 [1-3]; P=0.41). DEX provides reliable sedation with lower patient's satisfaction. A higher number of patients were discharged from the recovery room on vasopressors in the DEX group compare with the remifentanil group (5 vs. 0; P=0.045, respectively). The two groups showed a non-significant difference in the survival rate at 36-month (DEX 67% vs. remifentanil 73%; (P=0.90).
CONCLUSIONS:
In this setting remifentanil provides reliable sedation with higher patient's satisfaction and less hemodynamic effect than DEX.
AuthorsFabrizio Monaco, Gaia Barucco, Caterina C Lerose, Monica DE Luca, Margherita Licheri, Marta Mucchetti, Rosa Labanca, Federica Morselli, Cristina Mattioli, Federica Russetti, Alberto Zangrillo
JournalMinerva anestesiologica (Minerva Anestesiol) Vol. 89 Issue 4 Pg. 256-264 (04 2023) ISSN: 1827-1596 [Electronic] Italy
PMID36651372 (Publication Type: Journal Article)
Chemical References
  • Remifentanil
  • Dexmedetomidine
  • Hypnotics and Sedatives
  • Anesthetics
Topics
  • Humans
  • Remifentanil
  • Dexmedetomidine
  • Hypnotics and Sedatives
  • Retrospective Studies
  • Follow-Up Studies
  • Anesthetics
  • Aortic Aneurysm

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: